The Use of Machine Learning in Regulatory Drug Safety Evaluation

被引:3
|
作者
Zhang, Di [1 ]
Song, Jaejoon [1 ]
Dharmarajan, Sai [1 ]
Jung, Tae Hyun [1 ]
Lee, Hana [1 ]
Ma, Yong [1 ]
Zhang, Rongmei [1 ]
Levenson, Mark [1 ]
机构
[1] US FDA, Div Biometr 7, Off Biostat, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
来源
关键词
Causal inference; Prediction; Post-marketing; Natural language processing; Real-world data; Real-world evidence; CAUSAL INFERENCE; PRODUCT-SAFETY;
D O I
10.1080/19466315.2022.2108135
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
There has been growing interest of using machine learning (ML) methods with real-world data (RWD) to generate real-world evidence (RWE) to support regulatory decisions. In the U.S. Food and Drug Administration (FDA), ML has been applied in both prediction and causal inference problems for drug safety evaluation. The ML applications include health outcome identification, missing data imputation, risk factor identification, drug utilization discovery and causal inference study. We demonstrate the present utility and future potential of ML for regulatory science. We then discuss the challenges and considerations when using ML methods with RWD to generate RWE. Specifically, we focus on the transparency and reproducibility issue of using ML, the potential of ML and natural language processing (NLP) for missing data in RWD, training data issue for rare events, and interpretability of studies using ML.
引用
收藏
页码:519 / 523
页数:5
相关论文
共 50 条
  • [1] Drug safety assessment by machine learning models
    Xi, Nan Miles
    Huang, Dalong Patrick
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024,
  • [2] Unifying Evaluation of Machine Learning Safety Monitors
    Guerin, Joris
    Ferreira, Raul Sena
    Delmas, Kevin
    Guiochet, Jeremie
    2022 IEEE 33RD INTERNATIONAL SYMPOSIUM ON SOFTWARE RELIABILITY ENGINEERING (ISSRE 2022), 2022, : 414 - 422
  • [3] Machine learning models for classification tasks related to drug safety
    Anita Rácz
    Dávid Bajusz
    Ramón Alain Miranda-Quintana
    Károly Héberger
    Molecular Diversity, 2021, 25 : 1409 - 1424
  • [4] Applications of Artificial Intelligence and Machine Learning in Pharmacovigilance and Drug Safety
    Safaian, Karou
    Mosallam, Grace
    DRUG SAFETY, 2024, 47 (12) : 1398 - 1399
  • [5] Machine learning models for classification tasks related to drug safety
    Racz, Anita
    Bajusz, David
    Miranda-Quintana, Ramon Alain
    Heberger, Karoly
    MOLECULAR DIVERSITY, 2021, 25 (03) : 1409 - 1424
  • [6] A decade of drug metabolite safety testing: industry and regulatory shared learning
    Luffer-Atlas, Debra
    Atrakchi, Aisar
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2017, 13 (09) : 897 - 900
  • [7] On the use of machine learning methods for modern drug discovery
    Soto, Axel J.
    AI COMMUNICATIONS, 2011, 24 (01) : 99 - 100
  • [8] ANALYSIS OF THE CAUSES OF DRUG USE BY MEANS OF MACHINE LEARNING
    Leyva Vazquez, Maikel Yelandi
    Hernandez Cevallos, Remigio Edmundo
    Cruz Piza, Iyo Alexis
    Perez Teruel, Karina
    REVISTA UNIVERSIDAD Y SOCIEDAD, 2021, 13 : 392 - 399
  • [9] Use of machine learning approaches for novel drug discovery
    Lima, Angelica Nakagawa
    Philot, Eric Allison
    Goulart Trossini, Gustavo Henrique
    Barbour Scott, Luis Paulo
    Maltarollo, Vinicius Goncalves
    Honorio, Kathia Maria
    EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (03) : 225 - 239
  • [10] Regulatory Considerations on the use of Machine Learning based tools in Clinical Trials
    Maurizio Massella
    Diego Alejandro Dri
    Donatella Gramaglia
    Health and Technology, 2022, 12 : 1085 - 1096